Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

JB hospital sees surge in Singapore patients using MediSave for treatment

About 90 per cent of the patients using MediSave at Regency Specialist Hospital in Johor Bahru are women, with maternity-related care among the most common treatments.

JB hospital sees surge in Singapore patients using MediSave for treatment

Since the COVID-19 pandemic, the number of Singaporean patients using MediSave at Regency Specialist Hospital in Johor Bahru has doubled. Approximately 90% of these patients are women, with maternity-related care and obstetrics and gynaecology services being the most common treatments. The hospital, which has been participating in the scheme since 2010, does not disclose the exact number of MediSave patients.

Regency Specialist Hospital CEO Serena Yong noted that affordability and accessibility are key factors for patients seeking treatment across the Causeway. While treatment costs in Johor Bahru may be 10% cheaper than in Singapore, other factors such as quality, safety, and accessibility should also be considered. Patients should also factor in accommodation, time off work, and what MediSave will and will not cover overseas.

With the upcoming Johor Bahru-Singapore Rapid Transit System (RTS) Link opening in January 2027, cross-border healthcare could become even more accessible.

Written by urgent.news from Channel News Asia's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Read the original at channelnewsasia.com →

More in Health & Medicine

Mbah’s Drive to End Capital Flight in Health Tourism on Course

Emmanuel Ugwu-Nwogo in Umuahia Governor Peter Mbah’s drive to reverse medical tourism and halt the attendant capital flight remains on course, the Chief Executive Officer(CEO) of Enugu International…

  • Governor Peter Mbah aims to reduce capital flight through EIH.
  • Hospital will offer specialized cancer, cardiology, and orthopaedic care.
  • EIH to attract international patients with affordable, high-quality services.

Novo Nordisk FDA Setback Creates Opportunity for Korean CDMOs

Denmark’s Novo Nordisk, which has led the global pharmaceutical and biotech market on the back of explosive demand for the obesity treatments Wegovy and Ozempic, has run into an unexpected hurdle as…

  • FDA withholds approval for Novo Nordisk facilities due to quality-control violations.
  • Novo Nordisk's Bloomington facility received critical observations, including sterility failures.
  • Korean CDMOs like Celltrion and Samsung Biologics benefit from regulatory challenges.

More from Thursday 13 August →